Further, an assessment of the impact of the allelic state of TP53 on clinical outcomes in MDS patients suggested bi-allelic, but not mono-allelic, TP53 mutations are associated with high-risk disease, poor survival, and rapid transformation to leukemia [24]. This evidence concerns the gene TP53 and myelodysplastic syndrome.